SG11202006008WA - Anti-pd-l1 antibodies and uses thereof - Google Patents

Anti-pd-l1 antibodies and uses thereof

Info

Publication number
SG11202006008WA
SG11202006008WA SG11202006008WA SG11202006008WA SG11202006008WA SG 11202006008W A SG11202006008W A SG 11202006008WA SG 11202006008W A SG11202006008W A SG 11202006008WA SG 11202006008W A SG11202006008W A SG 11202006008WA SG 11202006008W A SG11202006008W A SG 11202006008WA
Authority
SG
Singapore
Prior art keywords
antibodies
Prior art date
Application number
SG11202006008WA
Other languages
English (en)
Inventor
Lei Fang
Yongqiang Wang
Zhengyi Wang
Bingshi Guo
Jingwu Zang
Original Assignee
I Mab Biopharma Us Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Us Ltd filed Critical I Mab Biopharma Us Ltd
Publication of SG11202006008WA publication Critical patent/SG11202006008WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202006008WA 2018-03-29 2019-03-29 Anti-pd-l1 antibodies and uses thereof SG11202006008WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018081079 2018-03-29
PCT/CN2019/080458 WO2019185029A1 (en) 2018-03-29 2019-03-29 Anti-pd-l1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11202006008WA true SG11202006008WA (en) 2020-07-29

Family

ID=68060946

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006008WA SG11202006008WA (en) 2018-03-29 2019-03-29 Anti-pd-l1 antibodies and uses thereof

Country Status (18)

Country Link
US (2) US11220546B2 (es)
EP (1) EP3589660A4 (es)
JP (1) JP7124257B2 (es)
KR (2) KR102475106B1 (es)
CN (1) CN110891975B (es)
AU (1) AU2019241339B2 (es)
BR (1) BR112020019827A2 (es)
CA (1) CA3086434C (es)
CL (1) CL2020002223A1 (es)
EA (1) EA202091590A1 (es)
IL (1) IL275734B (es)
MX (1) MX2020007842A (es)
MY (1) MY188237A (es)
PE (1) PE20210377A1 (es)
PH (1) PH12020551173A1 (es)
SG (1) SG11202006008WA (es)
UA (1) UA125918C2 (es)
WO (1) WO2019185029A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126905C2 (uk) * 2016-06-13 2023-02-22 Ай-Маб Байофарма Юес Лімітед Антитіло до pd-l1 та його застосування
CN112041348B (zh) * 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
CN113248618B (zh) * 2018-08-21 2022-03-18 天境生物科技(杭州)有限公司 抗pd-l1/抗lag3双特异性抗体及其用途
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
WO2021219092A1 (en) * 2020-04-30 2021-11-04 I-Mab Biopharma Co., Ltd. Pharmaceutical compositionscontaining anti-cd47 antibodies
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
CN114316045B (zh) * 2020-09-29 2024-07-12 英诺欧奇生物医药(苏州)有限公司 抗pd-l1抗体及其用途
CN113234162B (zh) * 2020-12-24 2022-05-13 四川大学华西医院 一种靶向cd133的嵌合抗原受体t细胞
EP4276466A1 (en) * 2021-01-08 2023-11-15 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding with pd-l1 and antigen-binding fragment of antibody
TW202346366A (zh) * 2022-04-02 2023-12-01 大陸商和鉑醫藥（上海）有限責任公司 標靶ｐｄ－ｌ１和ｃｄ４０的抗原結合蛋白及其製備和應用
WO2024104373A1 (en) * 2022-11-15 2024-05-23 I-Mab Biopharma Co., Ltd. Anti-pd-l1 nanobodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563193A (en) * 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2011043194A1 (en) 2009-10-09 2011-04-14 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device and method for manufacturing the same
EP3160505A4 (en) * 2014-07-03 2018-01-24 BeiGene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
LT3789402T (lt) * 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
CN107488229B (zh) * 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
UA126905C2 (uk) * 2016-06-13 2023-02-22 Ай-Маб Байофарма Юес Лімітед Антитіло до pd-l1 та його застосування
CN108777906B (zh) 2018-06-25 2020-06-16 珠海惠尔益电子科技有限公司 一种双灯组变焦电路及头灯
CN112041348B (zh) * 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
AU2019390274A1 (en) * 2018-11-30 2021-07-22 Abl Bio Inc. Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof

Also Published As

Publication number Publication date
PE20210377A1 (es) 2021-03-02
UA125918C2 (uk) 2022-07-06
CL2020002223A1 (es) 2021-01-29
CN110891975A (zh) 2020-03-17
AU2019241339B2 (en) 2021-08-12
KR102177931B1 (ko) 2020-11-13
MY188237A (en) 2021-11-24
CA3086434C (en) 2024-01-09
EP3589660A1 (en) 2020-01-08
KR20200130747A (ko) 2020-11-19
IL275734A (en) 2020-08-31
KR20190128716A (ko) 2019-11-18
EP3589660A4 (en) 2021-04-07
IL275734B (en) 2022-06-01
US20200157222A1 (en) 2020-05-21
WO2019185029A1 (en) 2019-10-03
JP2020518233A (ja) 2020-06-25
CN110891975B (zh) 2023-11-10
EA202091590A1 (ru) 2021-01-21
JP7124257B2 (ja) 2022-08-24
BR112020019827A2 (pt) 2021-01-05
CA3086434A1 (en) 2019-10-03
US11220546B2 (en) 2022-01-11
PH12020551173A1 (en) 2021-05-31
AU2019241339A1 (en) 2019-11-14
US20220119531A1 (en) 2022-04-21
KR102475106B1 (ko) 2022-12-08
MX2020007842A (es) 2020-09-25

Similar Documents

Publication Publication Date Title
IL273411A (en) Antibody against PD-L1 and its uses
IL276950A (en) Anti-CD73 antibodies and uses thereof
HK1259426A1 (zh) Pd-l1抗體及其用途
HK1255604A1 (zh) 抗pd-l1抗體及其用途
IL279455A (en) ANTI-PD-1 antibodies and their uses
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
IL282968A (en) Anti-NKG2A antibodies and their use
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL268051A (en) Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
ZA202006255B (en) Anti-pd-l1 antibody and use thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL281297A (en) Anti-NPR1 antibodies and uses thereof
IL276675A (en) Anti-PD-1 antibodies and uses thereof
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL283180A (en) Anti-PD-1 antibodies and their uses
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
IL285569A (en) Anti-pd-l1 antibody and use thereof
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
EP3774920A4 (en) ANTI-PD-L1 ANTIBODIES AND USE OF THESE LATEST